- Home
- LOAN vs SLS Comparison
LOAN vs SLS Comparison
Compare LOAN & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOAN
- SLS
- Stock Information
- Founded
- LOAN 1989
- SLS 2012
- Country
- LOAN United States
- SLS United States
- Employees
- LOAN N/A
- SLS N/A
- Industry
- LOAN Real Estate Investment Trusts
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- LOAN Real Estate
- SLS Health Care
- Exchange
- LOAN Nasdaq
- SLS Nasdaq
- Market Cap
- LOAN 61.4M
- SLS 70.1M
- IPO Year
- LOAN 1999
- SLS N/A
- Fundamental
- Price
- LOAN $5.67
- SLS $1.06
- Analyst Decision
- LOAN
- SLS
- Analyst Count
- LOAN 0
- SLS 0
- Target Price
- LOAN N/A
- SLS N/A
- AVG Volume (30 Days)
- LOAN 20.8K
- SLS 1.4M
- Earning Date
- LOAN 03-10-2025
- SLS 11-13-2024
- Dividend Yield
- LOAN 8.11%
- SLS N/A
- EPS Growth
- LOAN 6.53
- SLS N/A
- EPS
- LOAN 0.49
- SLS N/A
- Revenue
- LOAN $7,394,068.00
- SLS N/A
- Revenue This Year
- LOAN N/A
- SLS N/A
- Revenue Next Year
- LOAN N/A
- SLS N/A
- P/E Ratio
- LOAN $11.57
- SLS N/A
- Revenue Growth
- LOAN 5.79
- SLS N/A
- 52 Week Low
- LOAN $4.60
- SLS $0.50
- 52 Week High
- LOAN $5.90
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- LOAN 57.76
- SLS 55.79
- Support Level
- LOAN $5.30
- SLS $0.87
- Resistance Level
- LOAN $5.70
- SLS $1.01
- Average True Range (ATR)
- LOAN 0.12
- SLS 0.08
- MACD
- LOAN 0.00
- SLS 0.01
- Stochastic Oscillator
- LOAN 74.00
- SLS 73.08
About LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.